Peter Wehrwein is a journalist at Managed Healthcare Executive. He focuses on medicine and healthcare, covering a range of topics including medical specialties, health and wellness, and the healthcare system. Peter's work has been featured in notable publications such as Medical Economics, Dermatology Times, and Ophthalmology Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Peter Wehrwein's coverage suggests a strong focus on healthcare and pharmaceutical topics, often drawing from data and government announcements. Given this emphasis, he is likely to respond well to pitches that provide expert commentary or analysis of new research findings, policy changes in the healthcare sector, or insights into the pharmaceutical industry.
Pitches regarding medical breakthroughs, policy implications for healthcare providers and patients alike, as well as perspectives on upcoming trends in the medical field are likely to resonate with Peter.
As his geographic focus is national (United States), pitches should be tailored accordingly if they involve specific U.S.-focused developments within the healthcare & pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Wehrwein
The Wall Street Journal is reporting that President Donald Trump has signed off on Makary's dismissal.
Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup company focused on managing the cost and delivery fo cell and gene therapy.
By: Peter Wehrwein
The company says it made an upfront payment of $25 million for a global license to develop and commercialize the ARO-PHPLA3.
By: Peter Wehrwein
Politico reports that Kyle Diamantas will serve as acting FDA commissioner until a permanent replacement is named,
By: Peter Wehrwein
Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the company is looking to bridge the gaps among all stakeholders in burgeoning cell and gene therapy category.
By: Peter Wehrwein
Shrank is president and co-founder of cell and gene therapy (CGT) startup Aradigm, which is working with patients, payers, providers, and manufacturers to manage the cost and financial risk of expensive cell and gene therapy.
Nubeqa (darolutamide) may have fewer negative cognitive side effects because it doesn't cross the blood-brain barrier.
By: Peter Wehrwein
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
By: Peter Wehrwein
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
By: Peter Wehrwein
Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B.B.S.
